Your AI Regulatory Research Assistant
Ask regulatory questions and get cited answers from FDA, ICH, and EU documents.
Try It NowRegulatory Research, Reimagined
Instant Regulatory Answers
Ask in plain English. Get answers from official FDA, ICH, and EU sources.
Source Citations
See the document, section, and excerpt behind each answer.
Smarter Regulatory Search
Finds broad guidance and exact references like 21 CFR 312.32.
Ask Anything About Regulatory Compliance
Ask about audits, EU trial rules, GCP, guidance, or FDA approval issues. Every answer includes citations.
- FDA, CFR, guidance, warning letters, and CRLs
- ICH GCP and international guidelines
- EU CTR, MDR, IVDR, GDPR, and EHDS
Regulatory AI Assistant
What are common FDA Complete Response Letter deficiencies for oncology drugs?
Based on FDA Complete Response Letters and FDA guidance, common oncology application deficiencies include:
1. Insufficient evidence of efficacy. CRLs often ask sponsors to provide additional analyses or another adequate and well-controlled trial when the submitted clinical evidence does not support approval.
2. Unresolved product quality or manufacturing issues. FDA frequently identifies CMC, facility inspection, or process validation deficiencies that must be addressed before approval.
3. Labeling and risk-management gaps, including safety updates, dosing language, or postmarketing commitments that need revision before resubmission.
FDA Complete Response Letter - NDA 215344
NDA 215344 CRL - Clinical and Clinical Pharmacology
"Provide additional clinical evidence and analyses adequate to support the proposed indication..."
Suggested questions
Powered by Real Regulatory Documents
Official sources, checked regularly, with stale documents flagged.
FDA Warning Letters
3,000+ FDA warning letters from fda.gov
3,000+
21 CFR (Code of Federal Regulations)
70+ clinically relevant Title 21 parts from eCFR.gov
70+ parts
ICH Guidelines
Quality, safety, efficacy, and multidisciplinary guidelines
130+ guidelines
FDA Guidance Documents
2,000+ official FDA guidance documents
2,000+ docs
EU Regulations
EUR-Lex acts for CTR, MDR, IVDR, GDPR, EHDS, and more
90+ acts
FDA Complete Response Letters
FDA deficiency letters for NDA and BLA applications
438 letters
Checked On A Schedule
Warning letters daily. CFR, FDA guidance, ICH, EU regulations, and CRLs weekly.
Updated Directly From Source
New releases come straight from FDA, eCFR.gov, ICH, and EUR-Lex, not from stale AI training data.
Outdated Documents Are Flagged
Withdrawn, superseded, and no-longer-in-force documents are marked clearly.
EU Commission health guidance is planned next.
Every Claim Backed by Source Documents
Every answer shows where it came from, so you can verify it fast.
- Inline citations
- Exact excerpts
- Original document links
Source Citations
21 CFR 312.32 -- IND Safety Reporting
View Source
21 CFR 312.32(c)(1)(i)
"The investigator must report to the sponsor any adverse experience that is both serious and unexpected. Such reports must be made as soon as possible but no later than 24 hours after the investigator first learns of the event."
Warning Letter to Springfield Clinical Research
View Source
January 2025
"Your firm failed to report adverse experiences to the sponsor and IRB as required. Specifically, 12 serious adverse events were not reported within the required timeframes, and 4 events were not reported at all during the course of the study."
Regulation (EU) No 536/2014 -- Clinical Trials Regulation
View Source
EU CTR Article 41
"The investigator shall record and document every adverse event or laboratory abnormality identified in the protocol as critical to the safety evaluation..."
Search query:
"adverse event reporting requirements under 21 CFR 312"
Exact Words Only
21 CFR 312.32 -- IND Safety Reporting
The sponsor shall report to FDA and investigators...
21 CFR 312.64 -- Investigator Reports
Progress reports per 21 CFR 312.33...
21 CFR 312.310 -- Individual Patient Access
Contains string "312" but unrelated to AE reporting...
Concept Only
ICH E6(R2) Section 4.11 -- Safety Reporting
The investigator should report all serious adverse events...
Warning Letter: AE Reporting Failure
Failed to maintain adequate adverse event records...
ICH E2A -- Clinical Safety Data Management
Definitions for expedited reporting of AEs...
Tundra Search
21 CFR 312.32 -- IND Safety Reporting
The sponsor shall report to FDA and investigators...
ICH E6(R2) Section 4.11 -- Safety Reporting
The investigator should report all serious adverse events...
Warning Letter: AE Reporting Failure
Failed to maintain adequate adverse event records...
Exact Words Only
21 CFR 312.32 -- IND Safety Reporting
The sponsor shall report to FDA and investigators...
21 CFR 312.64 -- Investigator Reports
Progress reports per 21 CFR 312.33...
21 CFR 312.310 -- Individual Patient Access
Contains string "312" but unrelated to AE reporting...
Concept Only
ICH E6(R2) Section 4.11 -- Safety Reporting
The investigator should report all serious adverse events...
Warning Letter: AE Reporting Failure
Failed to maintain adequate adverse event records...
ICH E2A -- Clinical Safety Data Management
Definitions for expedited reporting of AEs...
Tundra Search
21 CFR 312.32 -- IND Safety Reporting
The sponsor shall report to FDA and investigators...
ICH E6(R2) Section 4.11 -- Safety Reporting
The investigator should report all serious adverse events...
Warning Letter: AE Reporting Failure
Failed to maintain adequate adverse event records...
Find the Right Regulatory Text Faster
Tundra finds the relevant rule, guidance, or enforcement example behind the answer.
- Plain-English questions
- Exact citations and application numbers
- Source-backed excerpts
How It Works
From question to cited answer in seconds.
1
Ask a Question
Type your regulatory question in plain English
2
Review Relevant Sources
Tundra finds the most relevant regulatory text
3
AI Generates Answer
Answers grounded in real documents, not hallucinations
4
Verify Citations
Check source text and document links for every claim
3,000+
FDA warning letters available
70+
21 CFR parts searchable
84%
Citation-backed retrieval precision
<2s
Average response time
Stop Digging Through Regulations Manually
Get cited answers from FDA, ICH, and EU sources in seconds.